Share This

Public company info - Wuxi Biologics (Cayman) Inc. , 02269.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Wuxi Biologics (Cayman) Inc., 02269.HK - Cash Flow 2022-12 2021-12 2020-12 2019-12 2018-12 2017-12 2016-12 2015-12 2014-12
Net Cash Flow from Operating Activities 6,127,335 3,781,244 1,975,514 1,286,080 813,710 403,615 129,382 107,150 21,505
Net Cash Flow from Return on Investments & Servicing of Finance 11,540 -15,208 -3,909 3,817 79,755 -33,619 -30,399 -20,590 -2,556
　Interest Received 112,593 67,992 78,635 53,618 79,755 3,149 0 0 0
　Interest Paid -108,239 -83,200 -82,544 -49,801 0 -36,768 -30,399 -2,531 -2,556
　Dividend Received 8,315 0 0 0 0 0 0 0 0
　Dividend Paid -1,129 0 0 0 0 0 0 -18,059 0
　Others 0 0 0 0 0 0 0 0 0
Taxes (Paid) / Refunded -585,662 -349,986 -94,238 -78,001 -52,103 -43,335 -47,461 0 0
Net Cash Flow from Investing Activities -6,028,031 -9,669,662 -7,294,918 -4,547,548 -495,829 -2,216,400 -421,144 -336,216 -50,120
　Additions to Fixed Assets -5,868,390 -6,523,114 -6,024,780 -3,233,464 -1,340,586 -670,601 -428,883 -334,362 -51,044
　Disposal of Fixed Assets 20,125 80,856 66,485 47,645 530 50 0 66 46
　Increase in Investments -10,098,514 -60,671,006 -18,028,821 -4,777,430 -1,057,205 -1,909,886 0 0 0
　Decrease in Investments 8,937,049 56,982,317 18,172,289 3,748,613 1,444,708 1,275,430 0 0 0
　Net Cash Flow with Related Parties 579,939 0 216,892 0 600 -278,083 -541,838 402,398 32,992
　Others 401,760 461,285 -1,696,983 -332,912 456,124 -633,310 549,577 -404,318 -32,114
Net Cash Flow before Financing Activities -474,818 -6,253,612 -5,417,551 -3,335,652 345,533 -1,889,739 -369,622 -249,656 -31,171
Net Cash Flow from Financing Activities -2,483,353 8,292,659 6,648,188 5,462,624 3,206,824 2,266,075 363,162 397,990 32,992
　New Loans 2,389,197 675,284 1,171,239 2,049,825 0 346,585 918,000 0 4,424
　Loans Repayment -2,684,215 -822,110 -349,859 -162,174 0 -1,238,616 -13,000 -4,408 -4,424
　Fixed Income/Debt Instruments 0 0 0 0 0 0 0 0 0
　Repayment of Fixed Income/Debt Instruments 0 0 0 0 0 0 0 0 0
　Equity Financing 36,180 10,956,600 5,609,916 3,574,973 3,206,224 3,436,189 0 0 0
　Net Cash Flow with Related Parties 579,939 0 216,892 0 600 -278,083 -541,838 402,398 32,992
　Others -2,804,454 -2,517,115 0 0 0 0 0 0 0
Increase(Decrease) in Cash & Cash Equivalents -2,958,171 2,039,047 1,230,637 2,126,972 3,552,357 376,336 -6,460 148,334 1,821
Cash & Cash Equivalents at Beginning of Year 9,003,280 7,095,735 6,205,496 4,084,395 503,881 169,102 158,229 5,948 4,176
Net Cash Flow due to Change in Exchange Rate/Others 350,113 -131,502 -340,398 -5,871 28,157 -41,557 17,333 3,947 -49
Cash & Cash Equivalents at End of Year 6,395,222 9,003,280 7,095,735 6,205,496 4,084,395 503,881 169,102 158,229 5,948
Currency Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi
Unit
Auditor's Opinion 1 1 1 1 1 1 0 0 0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.